Disclosure information not submitted.
P-408: Survival Analysis of Selinexor-Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Real-World Exploratory Analysis
Wednesday, September 25, 20246:20 PM – 6:40 PM East Coast USA Time
P-409: Real-Life Outcomes in Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Carfilzomib- and/or Pomalidomide-Based Regimens in the LocoMMotion and MoMMent Studies
Wednesday, September 25, 20246:40 PM – 7:00 PM East Coast USA Time
